The expansion signals in the United States turned by $ 50 billion in the manufacture of medicines amid the threat of tariffs

The expansion signals in the United States are worth $ 50 billion in the manufacture of medicines, amid a threat of tariffs

Astrazneca invests $ 50 billion in US operations by 2030, including the largest manufacturing factory in Virginia specialized in respiratory treatments, blood vessels, metabolism using artificial intelligence and advanced techniques.

The project will create hundreds of highly skilled jobs and enhance American pharmaceutical supply chains, and are compatible with politics’s concentration on production reproduction.

This step coincides with the Trump administration policies, including 200 percent possible tariffs on imported drugs, urges companies to transfer production to the United States to avoid sanctions.

Astrazneca CEO (42 percent of revenue) as a growth key, while Virginia Governor Glenn Youngin describes the deal – in 33 days – as a model for rapid economic development.

Other Varma giants (for example, Roche, Eli Lily) are investing billions of dollars locally, but critics warn of customs tariffs against drug lack. White House counters that local production is crucial for national security.

Astrazneca, an Anglo-Suwaid pharmaceutical company, is investing one of the largest pharmaceutical companies in the world, $ 50 billion in US operations by 2030- Including the construction of its largest manufacturing facility ever in Virginia.

Virginia Governor Glenn Yongen announced the planned Astrazeneca factory on Monday, July 21. The facility, whose location has not yet been located in the production of respiratory treatments and cardiovascular diseases will be specialized in using artificial intelligence and advanced manufacturing techniques. It will become a broadcaster to expand the United States for EstrazzinicaCreate hundreds of highly skilled jobs while strengthening the increasingly urgent local supply chains for policy makers.

The advertisement reflects the direction of a wider industry towards drug production. At a time when the second Trump administration pays aggressive commercial policies, Including potential tariffs of up to 200 percent on imported drugs.

President Donald Trump, who referred to investing in the Oval Office’s observations on Tuesday, has framing the company’s commitment in response to commercial policy and the larger management agenda. The CEO said that the pharmaceutical company will spend its investments “to build different places throughout the country, large manufacturing factories, and pharmaceutical plants.”

Trade Secretary Howard Lootnick likeld a step Astrazzinica, echoing the administration’s boost to reduce dependence on foreign -made drugs. “This historical investment brings tens of thousands of jobs to the United States and will ensure the production of medicine in our country here,” he said in a statement.

Astrazeneca’s US Bet

Pascal Soreriot, CEO of Astrazeneca, confirmed that the American market-which already represents 42 percent of the $ 54 billion annual revenue for the company-is still essential in the long-term growth strategy. Yongen praised the Virginia deal, which was negotiated according to it in just 33 days, as a model for rapid economic development.

This step comes amid the escalation of commercial tensions. In May, Trump suggested a sharp tariff for imported drugs. The companies warned that it was “almost a year and a half” to transfer production before facing the sanctions.

Indeed, multiple drug giants-including Roche, Elie Lily, Johnson & Johnson-revealed billions of dollars in investment plans in the United States this year. Some industry analysts view these obligations as preventive measures to avoid future trade restrictions, although Astrazeneca insists that its decision is compatible with financial and strategic goals.

Critics warn that customs tariffs can disrupt supply chains, especially for public medicines. In April, the Association of Medicines, which represents low -cost manufacturers, has warned in April that these policies risk the exacerbation of the shortage, which urges coordination between industry and policy makers.

However, the White House confirms that the expansion of local manufacturing is vital to national security. The executive order signed by Trump on May 5, Federal Agencies, is directed to accelerate permits for the US -based pharmaceutical plants, simplifying Food and Drug Administration Reviews and impose higher fees on foreign facilities. (Related to: Trump’s executive, targeting Big Pharma, aims to reduce drug prices by up to 80 %))

For Astrazeneca, Virginia project is just one component of the expansion of the United States. The company also plans for promotions to research centers in Maryland and Massachusetts, California genetic facilities and Indiana and clinical trial supplies-which indicates a long-term bet on American pharmaceutical innovation.

Go BigPharmanews.com For more similar stories.

He watches The CEO of Astrazeneca Pascal Soirot, expressing an agreement with President Trump’s order to reduce drug prices In this clip.

This video from Newslips on Brighton.com.